BR112013011441A2 - composto, composição farmacêutica, e, uso de um composto - Google Patents
composto, composição farmacêutica, e, uso de um compostoInfo
- Publication number
- BR112013011441A2 BR112013011441A2 BR112013011441A BR112013011441A BR112013011441A2 BR 112013011441 A2 BR112013011441 A2 BR 112013011441A2 BR 112013011441 A BR112013011441 A BR 112013011441A BR 112013011441 A BR112013011441 A BR 112013011441A BR 112013011441 A2 BR112013011441 A2 BR 112013011441A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutical composition
- compounds
- deficiency
- glycosities
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
- C07H9/06—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing nitrogen as ring hetero atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
Abstract
composto, composição farmacêutica, e, uso de um composto. a invenção diz respeito aos compostos para inibir seletivamente glicosidades, usos dos compostos e composições farmacêuticas que incluem os compostos, e aos métodos de tratar doenças e distúrbios relacionados à deficiência ou superexpressão de o-glcnacase, e/ou acúmulo ou deficiciência de o-glcnac.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNPCT/CN2010/078528 | 2010-11-08 | ||
PCT/CN2010/078528 WO2012061972A1 (en) | 2010-11-08 | 2010-11-08 | Selective glycosidase inhibitors and uses thereof |
US41859610P | 2010-12-01 | 2010-12-01 | |
US61/418596 | 2010-12-01 | ||
PCT/CN2011/080691 WO2012062157A1 (en) | 2010-11-08 | 2011-10-12 | Pyrano[3,2-d]thiazol derivatives and uses thereof as selective glycosidase inhibitors |
CNPCT/CN2011/080691 | 2011-10-12 | ||
PCT/US2011/059668 WO2012064680A1 (en) | 2010-11-08 | 2011-11-08 | Selective glycosidase inhibitors and uses thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
BR112013011441A2 true BR112013011441A2 (pt) | 2016-07-19 |
BR112013011441B1 BR112013011441B1 (pt) | 2021-11-09 |
BR112013011441B8 BR112013011441B8 (pt) | 2023-04-18 |
Family
ID=46051261
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013011441A BR112013011441B8 (pt) | 2010-11-08 | 2011-11-08 | Compostos inibidores seletivos de glicosidases, composição farmacêutica, e, uso de um composto |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP2637503B1 (pt) |
JP (1) | JP5965407B2 (pt) |
KR (1) | KR101922266B1 (pt) |
AR (1) | AR083798A1 (pt) |
AU (2) | AU2011326186A1 (pt) |
BR (1) | BR112013011441B8 (pt) |
CA (1) | CA2816798C (pt) |
ES (1) | ES2600028T3 (pt) |
MX (1) | MX336611B (pt) |
RU (1) | RU2592285C2 (pt) |
TW (1) | TW201249848A (pt) |
WO (1) | WO2012064680A1 (pt) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010012107A1 (en) | 2008-08-01 | 2010-02-04 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
WO2011140640A1 (en) | 2010-05-11 | 2011-11-17 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
WO2012061927A1 (en) | 2010-11-08 | 2012-05-18 | Alectos Therapeutics, Inc. | Selective glycosidase inhibitors and uses thereof |
AU2011349021B2 (en) * | 2010-12-23 | 2016-12-22 | Alectos Therapeutics, Inc. | Selective glycosidase inhibitors and uses thereof |
US8927507B2 (en) | 2011-03-24 | 2015-01-06 | Ernest J. McEachern | Selective glycosidase inhibitors and uses thereof |
WO2012129651A1 (en) | 2011-03-31 | 2012-10-04 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
US9701693B2 (en) | 2011-06-27 | 2017-07-11 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
JP6147737B2 (ja) | 2011-06-27 | 2017-06-14 | アレクトス・セラピューティクス・インコーポレイテッド | 選択的グリコシダーゼ阻害剤およびその使用 |
WO2013000085A1 (en) | 2011-06-27 | 2013-01-03 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
KR102108586B1 (ko) * | 2012-05-08 | 2020-05-07 | 머크 샤프 앤드 돔 코포레이션 | 투과성 글리코시다제 억제제 및 그의 용도 |
US9809537B2 (en) | 2012-08-31 | 2017-11-07 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
US9670195B2 (en) | 2012-08-31 | 2017-06-06 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
RU2672873C2 (ru) * | 2012-10-31 | 2018-11-20 | Алектос Терапьютикс Инк. | Ингибиторы гликозидаз и их применения |
WO2014100934A1 (en) | 2012-12-24 | 2014-07-03 | Merck Sharp & Dohme Corp. | Glycosidase inhibitors and uses thereof |
JP6994819B2 (ja) | 2016-07-26 | 2022-02-04 | 三菱電機株式会社 | 照明具および照明装置 |
RU2748383C1 (ru) * | 2020-10-21 | 2021-05-25 | федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) | Способ терапии болезни Тея-Сакса и болезни Сандхоффа с помощью генетически модифицированных мезенхимных стволовых клеток человека со сверхэкспрессией β-гексозаминидазы A |
WO2024083820A1 (en) | 2022-10-18 | 2024-04-25 | Institut National de la Santé et de la Recherche Médicale | Method and composition for determining the level of o-glcnacylation in horses |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU1441749A1 (ru) * | 1987-03-16 | 1996-01-10 | Институт Тонкой Органической Химии Им.А.Л.Мнджояна | 2-АМИНО-5,5-ДИМЕТИЛ-4,5-ДИГИДРО-7Н-ПИРАНО [4,3-d] ТИАЗОЛ, ОБЛАДАЮЩИЙ ТРАНКВИЛИЗИРУЮЩЕЙ АКТИВНОСТЬЮ |
WO2006092049A1 (en) | 2005-03-01 | 2006-09-08 | Simon Fraser University | Selective glycosidase inhibitors, methods of making inhibitors, and uses thereof |
WO2008025170A1 (en) | 2006-08-31 | 2008-03-06 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
CA2732335A1 (en) | 2008-08-01 | 2010-02-04 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
WO2010012107A1 (en) | 2008-08-01 | 2010-02-04 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
US20110301217A1 (en) | 2008-09-16 | 2011-12-08 | David Jaro Vocadlo | Selective Glycosidase Inhibitors and Uses Thereof |
MX358463B (es) * | 2011-08-25 | 2018-08-22 | Merck Patent Gmbh | Pirano[3,2-d][1,3]tiazol como inhibidores de glicosidasa. |
-
2011
- 2011-11-07 TW TW100140566A patent/TW201249848A/zh unknown
- 2011-11-08 BR BR112013011441A patent/BR112013011441B8/pt active IP Right Grant
- 2011-11-08 RU RU2013126531/04A patent/RU2592285C2/ru active
- 2011-11-08 MX MX2013005118A patent/MX336611B/es unknown
- 2011-11-08 ES ES11840448.2T patent/ES2600028T3/es active Active
- 2011-11-08 AR ARP110104166A patent/AR083798A1/es unknown
- 2011-11-08 CA CA2816798A patent/CA2816798C/en active Active
- 2011-11-08 JP JP2013537923A patent/JP5965407B2/ja active Active
- 2011-11-08 EP EP11840448.2A patent/EP2637503B1/en active Active
- 2011-11-08 AU AU2011326186A patent/AU2011326186A1/en not_active Abandoned
- 2011-11-08 WO PCT/US2011/059668 patent/WO2012064680A1/en active Application Filing
- 2011-11-08 KR KR1020137014710A patent/KR101922266B1/ko active IP Right Grant
-
2016
- 2016-04-07 AU AU2016202186A patent/AU2016202186B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AR083798A1 (es) | 2013-03-20 |
MX2013005118A (es) | 2013-07-29 |
BR112013011441B8 (pt) | 2023-04-18 |
RU2013126531A (ru) | 2014-12-20 |
EP2637503A1 (en) | 2013-09-18 |
ES2600028T3 (es) | 2017-02-06 |
TW201249848A (en) | 2012-12-16 |
EP2637503B1 (en) | 2016-09-14 |
AU2011326186A8 (en) | 2013-08-01 |
WO2012064680A1 (en) | 2012-05-18 |
CA2816798A1 (en) | 2012-05-18 |
RU2592285C2 (ru) | 2016-07-20 |
MX336611B (es) | 2016-01-22 |
KR20130129974A (ko) | 2013-11-29 |
JP5965407B2 (ja) | 2016-08-03 |
CA2816798C (en) | 2019-02-26 |
AU2011326186A1 (en) | 2013-05-23 |
EP2637503A4 (en) | 2014-04-09 |
JP2013541596A (ja) | 2013-11-14 |
AU2016202186B2 (en) | 2017-10-12 |
BR112013011441B1 (pt) | 2021-11-09 |
AU2016202186A1 (en) | 2016-04-28 |
KR101922266B1 (ko) | 2018-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013011441A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
BR112013033098B8 (pt) | inibidores de glicosidade seletivos e usos dos mesmos | |
BR112015029969A2 (pt) | tratamento de câncer usando moduladores de isoformas quinase pi3 | |
BR112018008918A2 (pt) | compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos | |
BR112014030655A8 (pt) | Compostos inibidores de pirimidinil tirosina quinase, e composição farmacêutica que os compreende | |
BR112014010206B8 (pt) | composto derivado de piridopirazina, composição farmacêutica, e, uso de um composto | |
BR112014009415A2 (pt) | inibidores de arginase e suas aplicações terapêuticas | |
UY33597A (es) | Compuestos y composiciones como inhibidores de la trk | |
BR112014003681A2 (pt) | composto, composição farmacêutica, produto de combinação farmacêutica, uso de um composto, e, método para tratar doenças ou condições | |
CU20130115A7 (es) | Compuestos y composiciones como inhibidores de trk | |
BR112015009638A2 (pt) | inibidores de glicosidase e usos dos mesmos | |
BR112016015706A8 (pt) | composto, uso do mesmo e composição farmacêutica | |
BR112014010183B8 (pt) | Composto, composição farmacêutica, produto, e, uso de um composto | |
BR112013027774A2 (pt) | novos compostos como moduladores de proteína quinases | |
BR112016015449A8 (pt) | compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos | |
BR112014030743A2 (pt) | inibidores de neprilisina | |
BR112014029706A8 (pt) | Composto, composição farmacêutica, e, uso de um composto | |
EA200900983A1 (ru) | Соединения и композиции в качестве ингибиторов киназы | |
BRPI1008383A2 (pt) | composto, composição farmacêutica, método para prevenir, inibir ou tratar uma condição, e, uso de um composto | |
BR112015006019A2 (pt) | composto selecionado, composição farmacêutica, método para tratar uma doença ou distúrbio, uso de um composto, kit para tratar uma condição mediada por pim quinase e invenção. | |
BR112015011456A2 (pt) | compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m | |
BR112012007828A2 (pt) | compostos, processo para preparar os compostos, e, composição farmacêutica. | |
BR112014017021A8 (pt) | inibidores de irak e usos dos mesmos | |
BRPI0813499B8 (pt) | compostos pirimidina carboxamidas úteis como inibidores da quinase raf, composição farmacêutica compreendendo os mesmos e método de preparação dos mesmos | |
EA201500175A1 (ru) | Соединения и композиции в качестве ингибиторов протеинкиназ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/11/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |
|
B25A | Requested transfer of rights approved |
Owner name: ALECTOS THERAPEUTICS INC. (CA) ; MERCK SHARP AND DOHME LLC (US) |